SCHEMBL13341575

SCHEMBL13341575

O=c1n(Cc2ccc(Cl)cc2Cl)nc2c3ccccc3nc(Cl)n12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPSR1 Q6W5P4 2/20 0.50
▸ TSHR P16473 2/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ CYP3A4 P08684 1/20 0.50
▸ CYP2D6 P10635 1/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ PMP22 Q01453 1/20 0.50
▸ HIF1A Q16665 1/20 0.50
▸ SLC9A1 P19634 1/20 0.47
▸ ALDH1A1 P00352 3/20 0.46
▸ KDM4E B2RXH2 3/20 0.46
▸ HPGD P15428 2/20 0.46
▸ GLA P06280 1/20 0.46
▸ VDR P11473 1/20 0.43
▸ LMNA P02545 6/20 0.43
▸ SMN1; SMN2 Q16637 4/20 0.43
▸ HTT P42858 3/20 0.43
▸ MAPT P10636 1/20 0.43
▸ TP53 P04637 1/20 0.42
▸ GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8220813 0.89 MEN1 (0.39) NPSR1TSHRCYP1A2CYP3A4CYP2D6
SCHEMBL8221499 0.89 NPSR1 (0.48) NPSR1TSHRCYP1A2CYP3A4CYP2D6
SCHEMBL13341459 0.83 ADORA2A (0.49) TSHRCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL8220814 0.80 ADORA2A (0.46) NPSR1TSHRCYP1A2CYP3A4CYP2D6
SCHEMBL8221012 0.77 ADORA2A (0.46) —
SCHEMBL8224740 0.77 TNF (0.51) NPSR1CYP1A2CYP3A4CYP2C9ALDH1A1
SCHEMBL8224052 0.74 ADORA2A (0.43) —
SCHEMBL8221845 0.73 ADORA2A (0.55) NPSR1TSHRCYP1A2CYP3A4CYP2D6
SCHEMBL8221183 0.72 ADORA2A (0.47) CYP1A2CYP3A4CYP2C9LMNAMAPT
SCHEMBL8223855 0.72 ADORA2A (0.64) MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7713985-B2 Adenosine Aa2 receptor antagonists SCHERING CORPORATION (US) 2010-05-11 — — US disclosed
US-7713985-B2 Adenosine Aa2 receptor antagonists SCHERING CORPORATION (US) 2010-05-11 — — US disclosed
EP-2038285-B1 ADENOSINE A2A RECEPTOR ANTAGONISTS SCHERING CORP (US) 2010-02-17 — — EP disclosed
US-20080255156-A1 ADENOSINE A2A RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LLC 2008-10-16 — — US disclosed
US-20080255156-A1 ADENOSINE A2A RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LLC 2008-10-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255156-A1 ADENOSINE A2A RECEPTOR ANTAGONISTS ADORA3, ADORA2A, ADORA1 NPSR1 157/4885TSHR 148/4885CYP1A2 1308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback